Peraso receives Nasdaq notice of minimum bid price deficiency, gains 180-day cure period
Peraso Inc. received a letter from Nasdaq on July 21, 2026, indicating the company no longer meets the minimum bid price requirement of $1 per share under Nasdaq Listing Rule 5550(a)(2), based on closing bid prices for the 30 consecutive business days ended July 20, 2026. The company has been provided 180 calendar days, or until January 19, 2027, to regain compliance; the closing bid price must reach at least $1 per share for a minimum of ten consecutive business days during this period. If compliance is not achieved, the company may be eligible for a second 180-day compliance period if it meets other continued listing standards and provides notice of intent to cure, potentially through a reverse stock split.
- closing bid price fell below $1 per share for 30 consecutive business days ended July 20, 2026
- 180-day cure period expires January 19, 2027
- closing bid price must reach at least $1 per share for a minimum of ten consecutive business days to regain compliance
- company may be eligible for a second 180-day compliance period if market value of publicly held shares and other Nasdaq Capital Market listing standards are met
- no immediate delisting; letter does not result in automatic Common Stock removal from Nasdaq Capital Market
Peraso faces a compliance deadline to restore its stock price to $1 or above; failure to do so within 180 days, or within an optional second cure period, could result in delisting from the Nasdaq Capital Market.
Derived from 8-K filed 2026-07-24. Not investment advice. Figures are extracted from the filing; prose is AI-assisted. View the source filing on SEC.gov →